RAAV1.tMCK.human-alpha-sarcoglycan- First cohort ( DrugBank: - )
1 disease
| ID | Disease name (Link within this page) | Number of trials |
|---|---|---|
| 113 | Muscular dystrophy | 1 |
113. Muscular dystrophy
Clinical trials : 646 / Drugs : 471 - (DrugBank : 105) / Drug target genes : 59 - Drug target pathways : 170
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT00494195 (ClinicalTrials.gov) | March 2008 | 27/6/2007 | Gene Transfer Therapy for Treating Children and Adults With Limb Girdle Muscular Dystrophy Type 2D (LGMD2D) | Phase I Gene Transfer of rAAV1.tMCK.Human-alpha-sarcoglycan for Limb Girdle Muscular Dystrophy Type 2D (LGMD2D) | Muscular Dystrophies | Genetic: rAAV1.tMCK.human-alpha-sarcoglycan- First cohort;Genetic: Genetic: rAAV1.tMCK.human-alpha-sarcoglycan- Second cohort | Nationwide Children's Hospital | National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS);Muscular Dystrophy Association | Completed | 5 Years | N/A | Both | 6 | Phase 1 | United States |